A Case of Valganciclovir Treatment for Cytomegalovirus Retinitis.
10.3341/jkos.2008.49.3.531
- Author:
Na Rae KIM
1
;
Yeon Sung MOON
;
Hee Seung CHIN
;
Jun Ho YOON
Author Information
1. Department of Ophthalmology, Inha University School of Medicine, Incheon, Koera.
- Publication Type:Case Report
- Keywords:
Cytomegalovirus Retinitis;
Ganciclovir;
Valganciclovir
- MeSH:
Administration, Oral;
Adult;
Cytomegalovirus;
Cytomegalovirus Retinitis;
Eye;
Follow-Up Studies;
Ganciclovir;
Humans;
Immunoglobulin G;
Immunoglobulin M;
Lymphoma, Non-Hodgkin;
Retinaldehyde;
Retinitis;
Serologic Tests;
Vision, Ocular
- From:Journal of the Korean Ophthalmological Society
2008;49(3):531-538
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report a case of a patient with cytomegalovirus (CMV) retinitis who was treated with oral valganciclovir. CASE SUMMARY: A 34-year-old man who had undergone anti-cancer chemotherapy for Non-Hodgkin lymphoma was referred to the ophthalmologic oncology clinic because of decreased vision in both eyes. Fundus examination showed white, opaque, and granular retinal lesions in both eyes, and a serologic test showed a positive response to CMV antibody IgG and a negative response to CMV antibody IgM. The patient received induction therapy with intravenous ganciclovir and maintenance therapy with oral valganciclovir 900 mg once daily. CMV retinitis reactivated 4 weeks after maintenance therapy was discontinued. At that point, the patient received induction therapy with oral valganciclovir 900 mg twice daily for 3 weeks and maintenance therapy with 900 mg once daily for 5 weeks. The retinal lesion disappeared and did not recur after oral administration of valganciclovir. The patient discontinued valganciclovir after 5 weeks of maintenance therapy, and CMV retinitis did not reactivate during 6 months of follow-up. CONCLUSIONS: Oral valganciclovir was clinically effective in the treatment of CMV retinitis in a patient who was treated with anti-cancer chemotherapy for non-Hodgkin lymphoma.
